Fighting Forgetfulness with Nanotechnology
October 17, 2018 | Max Planck Institute for Polymer ResearchEstimated reading time: 2 minutes
![](https://iconnect007.com/application/files/8316/3126/0780/nanotech.jpg)
About 29 million people around the world are affected by the disease "Alzheimer." In an international collaboration, scientists of the Max Planck Institute for Polymer Research (MPI-P) in Mainz together with teams from Italy, Great Britain, Belgium and the USA are now working together on an approach for a therapy. On the one hand, the goal is to understand the processes occurring in the brain that lead to the disease; on the other hand the development of a method for targeted drug delivery.
In the human brain, nerve cells—so-called neurons—care for the transmission of electrical signals. They form the functional component responsible for sensations, stimuli and memories. In the presence of dementia, there is an adsorption of proteins outside the neurons, which then leads to the death of the neuronal cells. How to prevent the death of neurons is still the subject of scientific research today.
In a recent transnational research project funded by the EU Joint Program on Neurodegenerative Disease Research (JPND), which is funded in Germany by the German Federal Ministry of Education and Research (BMBF), researchers are now trying to address this question.
While project partners in Italy, Great Britain, Belgium and the USA investigate the exact processes in the brain, the MPI-P explores methods to transport drugs. The overcoming of a natural barrier in the body—the so-called blood-brain barrier—represents the main challenge. Drugs to be used in the brain must be able to pass this barrier first before acting in the brain.
For this purpose, the Mainz scientists are working on nanocapsules that are supposed to overcome the barrier. On the one hand, it has to be taken care on a long circulation time of the nanocapsules in the blood in order to increase the probability of interaction with the target cells in the affected brain areas. For this, it is important to design the nanocapsules so that they are not directly excreted by kidney or liver. On the other hand, special "address labels"—consisting of proteins—must be placed on the capsule surface in order to be recognized and absorbed by the target cells, much like a key with a lock. "We are still filling our nanoscale capsules with dye," says Dr. Svenja Morsbach, group leader in the department of Prof. Katharina Landfester at the MPI-P. "If the transport through the blood-brain barrier with the nanocarriers works, we hope we can simply exchange the dye for a suitable drug."
The partners involved in the project in Italy, the United Kingdom, Belgium and the USA are examining the exact processes in the brain in parallel with the development of the transport system in Mainz. Here, so-called "exosomes" and "neurotrophic factors" are of major interest. Exosomes are small "miniature cells" that can be released by real cells to communicate with each other. These have a dimension of only about 100 nanometers—that is 100 billionths of a meter in size. At the same time, "neurotrophic factors" are biochemical messengers responsible for the growth and survival of nerve cells. The interaction of exosomes and neuron-stimulating factors is seen as the main focus for the understanding of dementia by researchers.
The project is designed for a period of three years and is funded with over one million euro, of which a share of more than 400,000 euros is attributed to the subproject of the Mainz scientists. The researchers hope that understanding the disease itself and developing a functioning transport system will be an important step in the treatment of dementia.
Suggested Items
Greg LaRocca Joins SIA as Director of Industry Research and Economic Policy
09/06/2024 | SIAThe Semiconductor Industry Association (SIA) announced Greg LaRocca has joined the SIA team as director of industry research and economic policy. LaRocca will lead SIA’s industry statistics, data analytics, and market research work.
Dr. Jennie Hwang to Deliver Course on AI Opportunities, Challenges, Possibilities at SMTAI
08/28/2024 | Dr. Jennie HwangDr. Jennie Hwang, Chair of AI Committee of National Academies/DoD AI study, Chair of Review Panel of National AI Institute of NSF, and Committee of Strategic Thinking for Engineering Research in the Era of Artificial Intelligence of NSF, brings broad-based information and insights through an integrated perspective to the AI course.
C3 AI Recognized by Constellation Research for Cross-Category Leadership in Artificial Intelligence and Machine Learning Platforms
08/23/2024 | BUSINESS WIREC3 AI, the Enterprise AI application software company, announced it was named to both the Constellation ShortList™ for Artificial Intelligence and Machine Learning Best-of-Breed Platforms and the Constellation ShortList™ for Artificial Intelligence and Machine Learning Cloud Platforms in Q3 2024.
New Center to Improve Robot Dexterity Selected to Receive Up to $52M
08/21/2024 | Northwestern UniversityA large multi-institutional collaboration, led by Northwestern University, has received $26 million from the National Science Foundation (NSF) to launch a new Engineering Research Center (ERC) dedicated to revolutionizing the ability of robots to amplify human labor.
Air Force Research Laboratory Awards BAE Systems $48M to Advance Military Intelligence Analysis Capabilities
08/09/2024 | BAE SystemsBAE Systems has been awarded a $48 million contract from the Air Force Research Laboratory to further advance the Insight system. Insight is a next-generation Intelligence, Surveillance, and Reconnaissance (ISR) exploitation and resource management system which uses multiple intelligence signal processing, domain analysis multi-level fusion, predictive analytics, machine learning, and automation to fill gaps in today's military intelligence analysis capability.